NCT05206019 is a Phase 1 clinical trial of Albuvirtide in HIV/AIDS, sponsored by Frontier Biotechnologies Inc..

Who is sponsoring NCT05206019?

NCT05206019 is sponsored by Frontier Biotechnologies Inc..

What drugs are being tested in NCT05206019?

Interventions in NCT05206019: Albuvirtide.

Is NCT05206019 still recruiting?

NCT05206019 is currently completed. Last updated 9 January 2023.

Last reviewed 2023-01-09 · How we verify

NCT05206019

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

Completed Phase 1 Last updated 9 January 2023

What this trial tests

Phase 1 trial testing Albuvirtide in HIV/AIDS in 30 participants. Completed in 2 May 2022.

Timeline

16 February 2022

Primary endpoint
17 April 2022

2 May 2022

Quick facts

Lead sponsor	Frontier Biotechnologies Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	30
Start date	16 February 2022
Primary completion	17 April 2022
Estimated completion	2 May 2022
Sites	1 location across China

Drugs / interventions tested

Albuvirtide — full drug profile →

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →

Sponsor

Frontier Biotechnologies Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center,randomized,open, single-dose, parallel-design study, which will be only enrolled Chinese healthy volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.
Marra M, Catalano A, Sinicropi MS, Ceramella J, et al · · 2024 · cited 7× · PMID 39339960 · DOI 10.3390/v16091484

Verify or expand the search:

Other trials of Albuvirtide

Trials testing the same drug.

NCT04560569 — Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection · Phase 2 · unknown
NCT04819347 — Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection · Phase 2 · unknown

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Frontier Biotechnologies Inc. trials

Trials by the same sponsor.

NCT05583812 — A Study of FB2001 for Inhalation in Healthy Chinese Adults · Phase 1 · completed
NCT05197179 — A Bridging Study of FB2001 in Healthy Subjects · Phase 1 · completed
NCT04560569 — Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection · Phase 2 · unknown
NCT04819347 — Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection · Phase 2 · unknown
NCT04766931 — The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05206019 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Frontier Biotechnologies Inc.
Last refreshed: 9 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05206019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing